LOXL2 Recombinant Antibody

$25 ug total protein per lane of various lysates (see on figure) probed with LOXL2 monoclonal antibody, unconjugated (bsm-54163R) at 1:2000 dilution and 4\u00b0C overnight incubation. Followed by conjugated secondary antibody incubation at r.t. for 60 min.$

25 ug total protein per lane of various lysates (see on figure) probed with LOXL2 monoclonal antibody, unconjugated (bsm-54163R) at 1:2000 dilution and 4\u00b0C overnight incubation. Followed by conjugated secondary antibody incubation at r.t. for 60 min.

Applications

Reactivity

Human

Overview
Catalog #	bsm-54163r-TR
Product Name	LOXL2 Recombinant Antibody
Applications	WB
Reactivity	Human
Specifications
Conjugation	Unconjugated
Host	Rabbit
Source	Synthetic peptide within Human LOXL2 aa 750 to the C-terminus
Clonality	Recombinant
Isotype	IgG
Concentration	Lot dependent
Purification	Purified by Protein A.
Storage Buffer	0.01M TBS (pH 7.4), 1% BSA, 0.02% Proclin 300, and 50% Glycerol
Storage Condition	Store at 4°C for up to 2 weeks. For long term storage, store at -20°C in small aliquots to prevent freeze-thaw cycles.
Target
Gene ID	4017
Swiss Prot	Q9Y4K0
Subcellular location	Nucleus, Secreted, Endoplasmic reticulum
Synonyms	Lysyl oxidase homolog 2; Lysyl oxidase-like protein 2; Lysyl oxidase-related protein 2; Lysyl oxidase-related protein WS9-14; LOXL2;
Background	Mediates the post-translational oxidative deamination of lysine residues on target proteins leading to the formation of deaminated lysine (allysine). When secreted in the extracellular matrix, promotes cross-linking of extracellular matrix proteins by mediating oxidative deamination of peptidyl lysine residues in precursors to fibrous collagen and elastin. Acts as a regulator of sprouting angiogenesis, probably via collagen IV scaffolding. When nuclear, acts as a transcription corepressor and specifically mediates deamination of trimethylated 'Lys-4' of histone H3 (H3K4me3), a specific tag for epigenetic transcriptional activation. Involved in epithelial to mesenchymal transition (EMT) via interaction with SNAI1 and participates in repression of E-cadherin, probably by mediating deamination of histone H3. Also involved in E-cadherin repression following hypoxia, a hallmark of epithelial to mesenchymal transition believed to amplify tumor aggressiveness, suggesting that it may play a role in tumor progression. Acts as a regulator of chondrocyte differentiation, probably by regulating the expression of factors that control chondrocyte differentiation.
Application Dilution
WB	1:300-5000